Suispirin, 1000 mg/g, oral powder for pigs

Main information

  • Trade name:
  • Suispirin
  • Pharmaceutical form:
  • Oral powder
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Suispirin
    Germany
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • acetylsalicylic acid
  • Therapeutic area:
  • Pigs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0364/001
  • Authorization date:
  • 28-09-2011
  • EU code:
  • UK/V/0364/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:October2011

AN:00512/2010

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Suispirin,1000mg/g,oralpowderforpigs

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

1.0gpowdercontains:

Activesubstance:

Acetylsalicylicacid 1000mg

3. PHARMACEUTICALFORM

Oralpowder.

Whitetoalmostwhitepowder.

4. CLINICALPARTICULARS

4.1Targetspecies

Pigs

4.2Indicationsforuse,specifyingthetargetspecies

Pig:

Supportivetreatmentforreductionofpyrexiaincombinationwith,appropriateanti-

infectivetherapy,ifnecessary.

4.3Contraindications

Donotuseincaseofhypersensitivitytotheactivesubstanceorincasesof

gastrointestinal

irritationandulcers,chronicgastro-intestinaldisorders,bronchospasm,liverfunction

impairmentornephropathies.

Donotuseinpregnantorlactatingsows.

Donotuseinpigletslessthan4weeksofage.

4.4Specialwarnings

Incombinedtreatmentwithtetracyclines,atreatmentintervalofatleastonehour

betweenthetwoactiveagentsisrecommended.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Itmustbeensuredthattheanimalsconsumesufficientwaterduringtreatment.

GiventhatSuispirinmayinhibitclottingofblood,itisrecommendedthatelectivesurgery

shouldnotbeperformedonanimalswithin7daysaftertheendoftreatment.

Issued:October2011

AN:00512/2010

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Donoteat,drinkorsmokewhilstusingthisproduct.Contactviatheskinormucous

membranesoftheusermustbeavoidedduetotheriskofsensitisation.Ifyouknowthat

youareallergictoaspirin,avoidcontactwiththisproduct.Usesuitableprotective

clothingwhenusingthisproduct,suchasglovesandafacemask.Washhandsandall

exposedskinafteruse.

4.6Adversereactions(frequencyandseriousness)

Gastrointestinalirritationmayoccurespeciallyinanimalswithpre-existing

gastrointestinaldisease.Suchirritationmayclinicallybemanifestedbyproductionof

blackmanureduetobloodlossinthegastrointestinaltract.

Inhibitionofnormalbloodclottingmayoccurincidentally.Ifthiseffectoccursitwillbe

reversibleandeffectswilldiminishwithinapproximately7days.

4.7Useduringpregnancy,lactationorlay

Donotuseduringthewholeofpregnancyandlactation.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Penicillins,sulphonamides

Asaresultofitshighplasmaproteinbinding,acetylsalicylicacidmaysuppressstrongly

bindingsubstancessuchaspenicillinsandsulphonamides,thereforepotentiatingtheir

effect.

Furosemide

Thediureticeffectoffurosemideisdecreased.Thismaycausesymptomsoftoxicityin

animalsreceivinghighaspirindoses.

Tetracyclines

Combinedadministrationofbufferedacetylsalicylicacidwithtetracyclinesmayleadto

chelateformation.

Aminoglycosideantibiotics

Acombinationofacetylsalicylicacidandaminoglycosideantibioticsleadstoincreased

nephrotoxicpotential.

Ascorbicacid,methionine,ammoniumchloride

Urinaryacidificationcausedbyascorbicacid,methionineorammoniumchlorideleads

todeceleratedrenalsalicylicacidsecretionwithheightenedriskoftoxicreactions.

Medicinesleadingtourinaryalkalinisation(sodiumhydrogencarbonate)

Therenalsecretionofsalicylicacidisacceleratedbythealkalinisationoftheurine

(sodiumhydrogencarbonate).

Non-steroidalanti-inflammatories

CombinationwithotherNSAIDsleadstoincreasedorintensifiedoccurrenceofside

effects,particularlywithinthegastro-intestinaltract.

Glucocorticoids

Simultaneousadministrationofglucocorticoidsincreasestheriskofgastro-intestinal

bleeding.

Issued:October2011

AN:00512/2010

4.9Amountstobeadministeredandadministrationroute

Oralpowderfortopdressinguse.

Foruseinindividualpigsonfarmswhereonlyasmallnumberofpigsaretoreceivethe

veterinarymedicinalproduct.

Pig:

30mgacetylsalicylicacid(correspondingto30mgoftheproduct)perkgBWtwice

daily.

Thetreatmentperiodis3consecutivedays.

Minimumbodyweightofpigstobetreated:11kg.

Treatmentisachievedbymixingtheproductwithapproximately50gor200g

(accordingtobodyweight)ofthenormaldietperpig.Formeasuringthecorrectamount

oftheveterinarymedicinalproductpleaseusetheenclosedscoopsaccordingtothe

dosagetablebelow.Non-medicatedfeedshouldonlybeofferedaftercomplete

consumptionofallthemedicatedfeed.Animalsshouldbeisolatedfromotheranimals

fortreatment.

Medicatedfeedshouldbefreshlypreparedbeforeeachadministration.

PigType Bodyweigh

t(kg) Gramsoftheproduct

peranimal(Twice

daily) Equalamountin

ml

(formeasuringthe

dosewith

scoops)

Weanerpig

(small) 11 0.33 0.4

Weanerpig(big) 25 0.75 1.0

Fatteningpig

(small) 50 1.50 2.0

Fatteningpig

(big) 100 3.00 4.0

Sow 250 7.50 10.0

Scoops –twoscoopsmeasuring0.4ml(=0.33goftheproduct)and3ml(=2.25gof

theproduct)aresupplied.

Part-consumedfeedmustbedisposedofwithotherwastefeedandnotgiventoother

animals.

Toavoidoverdosingthepigstobetreatedshouldbeweighedorbodyweightaccurately

estimatedbyanexperiencedperson.

Feedconsumptionmaybereducedinclinicallysickanimalsandalsoinolderpigs

thereforefeedintakemayneedtobeadjustedtoachievetargetdosageintake.The

correctquantityoftheproductshouldbethoroughlymixedwiththefeedinabucketor

similarreceptacle.Toachievegoodmixtureandhomogeneityapre-mixturecanbe

used.

Theproductshouldonlybeaddedtodrynon-pelletedfeed.Donotinuseinadryhopper

orasemiliquidfeeder.

Issued:October2011

AN:00512/2010

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Pigstoleratedosagesupto90mg/kgforupto6dayswithoutanysignificantadverse

effects.

Treatmentincaseofoverdose:discontinuetreatmentwithacetylsalicylicacid

immediatelyandinitiatesymptomatictreatment.Thealkalinisationoftheurinewith

sodiumhydrogencarbonatemayleadtoacceleratedsecretionofacetylsalicylicacidor

salicylicacid.

4.11Withdrawalperiod

Pig:

Meatandoffal:1day

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Otheranalgesicsandantipyretics,Salicylicacidand

derivatives

ATCvetcode:QN02BA01

5.1Pharmacodynamicproperties

Acetylsalicylicacidisawell-known,non-steroidalanti-inflammatoryandoneoftheweak

analgesics.Acetylsalicylicacidhasananti-inflammatoryeffect,aperipheralanalgesic

andantipyreticeffectanditinhibitsthrombocyteaggregation.

Theeffectivenessofacetylsalicylicacidisdueprimarilytotheinhibitionoftheenzyme

cyclooxygenase,responsiblefortheformationofprostaglandinsandthromboxanefrom

arachidonicacid.Prostaglandinsaresignificantcausesofinflammations,painand

fever.

5.2Pharmacokineticparticulars

Followingoraladministration,acetylsalicylicacidisabsorbedinthestomachandupper

smallintestinedependingonthestomachcontents,itspHvalueandevacuationtimeas

wellasthegalenicformulation.Itishydrolysedtoitsmainmetabolitesalicylicacidwithin

onlyafewminutes.Deacetylationbeginswiththeabsorbtionintothemucosaandtakes

placetoalargeextentduringfirstpassmetabolism.Particularlyhighconcentrationsof

themainmetabolite,salicylicacid,canbefoundinthestomachwall,liver,heart,lungs,

renalcortex,bloodplasma,bonemarrowandinflamedtissue.Relativelylow

concentrationsareobservedinnon-inflamedmuscle,fatandconnectivetissue.

Followingadministrationofacetylsalicylicacidtopigs,maximumplasmaconcentrations

ofsalicylicacidarereachedapproximately2to3hourspostadministrationviathefeed.

24hoursafterthefinalapplication,onlytracesofsalicylicacidcanbedetectedinthe

plasmaandtissue.

Thedistributionvolumeofsalicylicacidislow.Upto75%ofsalicylicacidisboundto

plasmaproteinsinpigs.Salicylatemayovercometheplacentalbarrier.

Theeliminationhalflifeincreaseswithincreasingacetylsalicylicaciddoses.Themean

terminalhalflifeforsalicylicacidaftertreatmentwiththeproductviathefeedwasfound

tobebetween1.8and3.7hours.

Followingconjugationintheliver,salicylicacidissecretedviathekidneys.Secretionis

acceleratedwithurinepHvaluesbetween5and8.

Issued:October2011

AN:00512/2010

6. PHARMACEUTICALPARTICULARS

6.1LISTOFEXCIPIENTS

None.

6.2Incompatibilities

Inabsenceofcompatibilitystudythisproductcannotbemixedwithotherveterinary

products.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:5years

Shelf-lifeafterfirstopeningtheimmediatepackaging: 6months

Shelf-lifeafteradditiontothefeedaccordingtodirections: 15hours

6.4.Specialprecautionsforstorage

Securelyreclosepart-usedcontainersorsachetsafteruse.

6.5Natureandcompositionofimmediatepackaging

1x100gpowderand10x100gpowderarefilledinsachetswithpaper/polyethylene/

aluminium/polyethylenefoil.

Polystyrenescoopsof0.4mland3mlareattached.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinal

productsshouldbedisposedofinaccordancewithlocalrequirements.

Issued:October2011

AN:00512/2010

7. MARKETINGAUTHORISATIONHOLDER

aniMedicaGmbH

ImSüdfeld9

48308Senden-Bösensell

Germany

8. MARKETINGAUTHORISATIONNUMBER

Vm24745/4013

9. DATEOFFIRSTAUTHORISATION

18October2011

10 DATEOFREVISIONOFTHETEXT

October2011

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Notapplicable.

1-12-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Published on: Fri, 30 Nov 2018 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with a genetically modified Trichoderma reesei (strain DP‐Nzd22) by DuPont. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The endo‐1,4‐β‐xylanase is intended to be used in distilled alcohol production, bakery and brewery. Residual amounts of total organic solids (TOS) are removed during the production of dis...

Europe - EFSA - European Food Safety Authority Publications

17-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Aspergillus oryzae (strain NZYM‐FA)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Aspergillus oryzae (strain NZYM‐FA)

Published on: Fri, 16 Nov 2018 The food enzyme is an endo‐1,4‐β‐xylanase (EC 3.2.1.8) produced with a genetically modified strain of Aspergillus oryzae by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This xylanase is intended to be used in baking and cereal‐based processes. Based on the proposed maximum use levels, dietary exposure to the food enzyme–total organic solids (TOS) was e...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐a‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐OC by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels recommended, dietary exposure to the food enzyme–...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐SO)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐SO)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐α‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐SO by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the food enzyme–total organi...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Published on: Wed, 14 Nov 2018 The food enzyme acetolactate decarboxylase (α‐acetolactate decarboxylase; EC 4.1.1.5) is produced with a genetically modified Bacillus licheniformis strain NZYM‐JB by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This acetolactate decarboxylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organi...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Published on: Wed, 07 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of the additive Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials. It is a family of mixtures combining the four lanthanides lanthanum (La), europium (Eu), gadolinium (Gd) and/or terbium (Tb) in different proportions as their 1,4‐benzene dicarboxylate complexes, used as a taggant in plastics for authentication and ...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with the genetically modified Bacillus subtilis strain LMG S‐24584 by Puratos N. V. The genetic modifications do not give rise to safety concerns. The Panel noted that, although the production strain was not detected in the food enzyme, recombinant DNA was present in all batches of the food enzyme tested. The food enzyme is intended to be used in baking processes. Based on the maximum use levels re...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from a genetically modified Aspergillus niger (strain NZYM‐BW)

Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from a genetically modified Aspergillus niger (strain NZYM‐BW)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucan 1,4‐α‐glucosidase (EC 3.2.1.3) is produced with the genetically modified Aspergillus niger strain NZYM‐BW by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The glucan 1,4‐α‐glucosidase food enzyme is intended to be used in distilled alcohol production and starch processing for the production of glucose syrups. Residu...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucoamylase (glucan 1,4‐α‐glucosidase; EC 3.2.1.3) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This glucoamylase is intended to be used in brewing processes and in starch processing for glucose syrups production. Residual amounts of total organic s...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in starch processing for glucose syrups production, beverage alcohol (distilling) processes and baking proces...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos (hop strobiles) when used as a sensory feed additive for all animal species. The additive is specified to containing 40% beta acids and less than 0.2% alpha acids. Known substances of conce...

Europe - EFSA - European Food Safety Authority Publications

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

12-9-2018

Kabinet investeert in eerste 1000 dagen kind

Kabinet investeert in eerste 1000 dagen kind

Van kinderwens tot 2-jarige peuter: de ontwikkeling die we in de eerste 1000 dagen als kind meemaken is cruciaal voor zowel een gezonde groei als de ontplooiing en kansen op latere leeftijd. Verreweg de meeste kinderen in Nederland groeien veilig en gezond op. Toch heeft ongeveer 14% van de kinderen in Nederland een ‘valse’ start door vroeggeboorte, een te laag geboortegewicht of een combinatie van beide. Minister Hugo de Jonge (VWS), gemeenten, partijen uit de geboortezorg en de jeugdgezondheidszorg (JG...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

29-8-2018

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Published on: Thu, 16 Aug 2018 00:00:00 +0200 4,15‐Diacetoxyscirpenol (DAS) is a mycotoxin primarily produced by Fusarium fungi and occurring predominantly in cereal grains. As requested by the European Commission, the EFSA Panel on Contaminants in the Food Chain (CONTAM) assessed the risk of DAS to human and animal health related to its presence in food and feed. Very limited information was available on toxicity and on toxicokinetics in experimental and farm animals. Due to the limitations in the avai...

Europe - EFSA - European Food Safety Authority Publications

17-5-2018

Shoreside Enterprises Issues Voluntary Nationwide Recall of 7K and Poseidon 4500 (Extreme 1000 Mg) Due to Presence of Undeclared Sildenafil and Tadalafil

Shoreside Enterprises Issues Voluntary Nationwide Recall of 7K and Poseidon 4500 (Extreme 1000 Mg) Due to Presence of Undeclared Sildenafil and Tadalafil

Shoreside Enterprises, Inc. is voluntarily recalling 7K (Lot specific: Lot #RO) and Poseidon 4500 (Extreme 1000 mg) (Lot specific: Lot #20117BL) to the consumer level. FDA analysis found the samples of these products to contain undeclared Sildenafil and/or Tadalafil. Sildenafil and Tadalafil are active ingredients in two FDA-approved prescription drugs used for the treatment of erectile dysfunction (ED).

FDA - U.S. Food and Drug Administration

3-8-2012

Danish Pharmacovigilance Update, 21 June 2012

Danish Pharmacovigilance Update, 21 June 2012

Among the topics covered in this issue of Danish Pharmacovigilance Update are: Decrease in the number of intoxications and suicide attempts using drugs containing acetylsalicylic acid or paracetamol.

Danish Medicines Agency

29-10-2018

Clopidogrel/Acetylsalicylic acid Zentiva (Sanofi-Aventis groupe)

Clopidogrel/Acetylsalicylic acid Zentiva (Sanofi-Aventis groupe)

Clopidogrel/Acetylsalicylic acid Zentiva (Active substance: clopidogrel / acetylsalicylic acid) - Centralised - 2-Monthly update - Commission Decision (2018)7249 of Mon, 29 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1144/WS1433/0051

Europe -DG Health and Food Safety

29-10-2018

DuoPlavin (Sanofi Clir SNC)

DuoPlavin (Sanofi Clir SNC)

DuoPlavin (Active substance: clopidogrel / acetylsalicylic acid) - Centralised - 2-Monthly update - Commission Decision (2018)7255 of Mon, 29 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1143/WS/1433/0050

Europe -DG Health and Food Safety